Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc has announced the signing of a reseller agreement between HealthTab Inc, the company's point-of-care testing solution, and Abbott Rapid Dx UK & Ireland.
The pharmacy service innovator said the agreement provides a foundation for HealthTab to purchase and distribute the Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.
“As we’ve grown in Canada substantially in collaboration with Abbott, we’re excited to take this winning model to the UK,” Avricore Health (TSX-V:AVCR, OTC:AVCRF) CEO Hector Bremner said in a statement.
“We believe the UK is one of the leading jurisdictions to bring more funding for pharmacists to deliver services and that demand for HealthTab will be significant,” he added.
Avricore noted there are over 13,000 pharmacies in the UK, serving a population of over 67 million people, of which, 96% live within 20 minutes by walking or using transit of a community pharmacy.
HealthTab is currently in over 530 pharmacies in Canada and is leading a move to greater sophistication in point-of-care testing in community pharmacies, bringing high-quality instruments, robust health data management and quality assurance, according to the company.
Avricore Health is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.
Contact Sean at sean@proactiveinvestors.com